ZEB2 and colorectal carcinoma: Although not used in the treatment of CRC, we used doxorubicin to investigate whether ZEB2 promotes apoptosis resistance by drug exclusion due to its intrinsic fluorescence properties and the fact that drug efflux mechanisms of doxorubicin oxaliplatin are similar [32].